ADVENTRX Pharmaceuticals, Inc. (ANX) Closes On Preferred Stock Offering
ADVENTRX Pharmaceuticals, Inc. reported the completion of an already disclosed sale of stock in a direct offering to several institutional investors. Rodman & Renshaw, LLC was the placement agent for the offering. ADVENTRX Pharmaceuticals, Inc. received gross proceeds of $19.2 million in the sale, and will use the proceeds to continue research on its main products, the acquisition of new products and general corporate purposes. ADVENTRX Pharmaceuticals, Inc. issued Series F convertible preferred stock to the investor group that is convertible into common shares of ADVENTRX Pharmaceuticals, Inc. at a conversion price of $3.7025 per share. The preferred stock also…